Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367696 | 0.95 | PTGS2 (0.39) | PTGS2PTGS1ALDH1A1ALOX15CA12 | |
| SCHEMBL4369881 | 0.89 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1ALOX15 | |
| SCHEMBL21682593 | 0.88 | PTGS2 (0.36) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL21682594 | 0.87 | PTGS2 (0.38) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL12889839 | 0.85 | PTGS2 (0.38) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL12889841 | 0.85 | PTGS2 (0.38) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL12889840 | 0.85 | PTGS2 (0.38) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL12889838 | 0.85 | PTGS2 (0.38) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL12889836 | 0.83 | PTGS2 (0.38) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL12889837 | 0.83 | PTGS2 (0.38) | PTGS2PTGS1MAPTCRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121665-B1 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2121664-B1 | DINITRATE DERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-10-16 | — | — | EP | disclosed |
| US-8367711-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8293777-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME, CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-09-20 | — | — | US | disclosed |
| US-8252825-B2 | Angiotensin II receptor antagonists | NICOX (IT) | 2012-08-28 | — | — | US | disclosed |
| US-8207208-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2373630-A1 | NITROOXY DERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2313417-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | Nicox S.A. (FR) | 2011-04-27 | — | — | EP | disclosed |
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2011-03-31 | — | — | US | disclosed |
| US-20080194660-A1 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| WO-2008076247-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076246-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076245-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1711457-A4 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2008-01-09 | — | — | EP | disclosed |
| EP-1711454-A4 | COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES OR CONDITIONS IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS | MERCK FROSST COMPANY (CA) | 2007-04-04 | — | — | EP | disclosed |
| EP-1711454-A1 | COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES OR CONDITIONS IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS | Merck Frosst Company (CA) | 2006-10-18 | — | — | EP | disclosed |
| EP-1711457-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Company (CA) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005070874-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070868-A1 | COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES OR CONDITIONS IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS | MERCK FROSST COMPANY (CA) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, AGT | PTGS2 428/4885PTGS1 656/4885ALDH1A1 2089/4885 |
| US-20080194660-A1 | Angiotensin II receptor antagonists | AGTR1, AGTR2, REN | PTGS2 1456/4885PTGS1 1479/4885ALDH1A1 3538/4885 |
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | PTGS2 1153/4885PTGS1 1114/4885ALDH1A1 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.